＜＜Back

Next＞＞

Vol. 33　Suppl. 1　2005

Opening Remarks

H. Kawasaki

Jpn Pharmacol Ther 2005　33(s1) s3

---

1．A study of colloidal scintigraphy and asialo-scintigraphy in non-alcoholic steatohepatitis

C. Koreeda, et al．

Jpn Pharmacol Ther 2005　33(s1) s9

---

2．Asialoscintigraphy to detect recurrent hepatitis C following living donor liver transplantation

SH. Kawa, et al．

Jpn Pharmacol Ther 2005　33(s1) s15

---

4．Hepatic reserve capacity and local recurrence after radiofrequency ablation therapy for hepatocellular carcinoma

K. Ono, et al．

Jpn Pharmacol Ther 2005　33(s1) s19

---

【Discussion 1～4】

Jpn Pharmacol Ther 2005　33(s1) s25

---

5．Helicobacter pylori may decrease hepatic iron accumulation in hepatitis C

Y. Sumida, et al．

Jpn Pharmacol Ther 2005　33(s1) s29

---

6．Porphyria cutanea tarda and hepatitis C virus infection
―A possible relationship―

Y. Horie, et al．

Jpn Pharmacol Ther 2005　33(s1) s33

---

7．Idiopathic porphyrin methabolic disorder of middle and old age
―Nutritional approach―

M. Kondo, et al．

Jpn Pharmacol Ther 2005　33(s1) s37

---

【Discussion 5～7】

Jpn Pharmacol Ther 2005　33(s1) s45

---

8．Suppressive effect of ursodeoxycholic acid on pro-inflammatory cytokine-induced secretory phospholipase A2 expression

T. Ikegami, et al．　

Jpn Pharmacol Ther 2005　33(s1) s47

---

9．Effect of bile acids and organic anions on the increased biliary glutathione excretion by genipin

M. Akashi, et al．　

Jpn Pharmacol Ther 2005　33(s1) s51

---

10．Impaired membrane trafficking of the bile salt export pump（BSEP/ABCB11）is responsible for the pathogenesis of progressive familial intrahepatic cholestasis II

H. Hayashi, et al．　

Jpn Pharmacol Ther 2005　33(s1) s53

---

【Discussion 8～10】　

Jpn Pharmacol Ther 2005　33(s1) s57

---

11．Biliary excretion of pitavastatin is mainly mediated by BCRP（ABCG2）

M. Hirano, et al．

Jpn Pharmacol Ther 2005　33(s1) s61

---

12．Investigation of the transporters responsible for hepatic transport of rosuvastatin, a novel HMG-CoA reductase inhibitor

S. Kitamura, et al．

Jpn Pharmacol Ther 2005　33(s1) s65

---

13．The impact of OATP1B1*1b haplotype on the pharmacokinetics of pravastatin, valsartan and temocapril

K. Maeda, et al．　

Jpn Pharmacol Ther 2005　33(s1) s71

---

【Discussion 11～13】

Jpn Pharmacol Ther 2004　33(s1) s77

---

14．A simple noninvasive index for fibrosis in chronic hepatitis C

M. Koda, et al．

Jpn Pharmacol Ther 2004　33(s1) s79

---

15．IL-1B and IL-1RN polymorphisms and the progression of liver fibrosis

M. Mandai, et al．　

Jpn Pharmacol Ther 2004　33(s1) s85

---

16．Basic study of PDGF-targeting therapeutic approach for liver fibrogenesis

H. Yoshiji, et al．　

Jpn Pharmacol Ther 2004　33(s1) s91

---

17．Bile acid-induced hepatic stellate cell activation

D. Komichi, et al．　

Jpn Pharmacol Ther 2004　33(s1) s97

---

【Discussion 14～17】

Jpn Pharmacol Ther 2004　33(s1) s101

---

18．The prevention mechanisms of taurine on hepatic damage and fibrosis via antioxidative stress

T. Miyazaki, et al．　

Jpn Pharmacol Ther 2004　33(s1) s105

---

19．Effects of estradiol and progesterone on generation of reactive oxygen species and TGF-β expression in the oxidative stress-induced activation of cultured rat hepatic stellate cells

T. Itagaki, et al．

Jpn Pharmacol Ther 2004　33(s1) s111

---

20．Antifibrotic effect of angiotensin-II-inhibitors on bile duct ligation-induced liver fibrosis

M. Ueki, et al．　

Jpn Pharmacol Ther 2004　33(s1) s117

---

【Discussion 18～20】

Jpn Pharmacol Ther 2004　33(s1) s121

---

Closing Remarks

Y. Murawaki

Jpn Pharmacol Ther 2004　33(s1) s125